China Health Industries Holdings Inc (CHHE) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of China Health Industries Holdings Inc $0.00, price $0.00, upside +0.0%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch China Health Industries Holdings Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others.
Show more
China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.
Stock analysis
China Health Industries Holdings Inc (CHHE) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
China Health Industries Holdings Inc reported revenue of $112K in FY2023 versus $9.3M in FY2019, a compound −66.9%/yr. Reported net income was −$409K in FY2023.
Key figures
Market cap $6.6K · P/S ratio 0.07 · EPS (TTM) $−0.0200 · Return on equity −6.9% · Return on assets (EBIT) 3.2% · Operating margin −163,513% · Revenue (TTM) $95.9K · EPS growth (YoY) −89.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 100% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 0%, CHHE screens cheaper than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−77.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−55.7%
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
’11
’12
’13
’14
’15
’16
’17
’18
’19
’20
’21
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7.1% (2018) → −1,651.7% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
Compare China Health Industries Holdings Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
Beats the industry median on 3/4 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside+0.0% · Above median
Profitability
Return on assets−3.3% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "China Health Industries Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/CHHE
Frequently asked questions
Is China Health Industries Holdings Inc (CHHE) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0001 versus the last price from Sep 25, 2026 of $0.0001, about +0% upside (fairly valued).
What is the fair value of CHHE?
Our model-based fair value for China Health Industries Holdings Inc is $0.0001 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0001.
What is the quality score of CHHE?
China Health Industries Holdings Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for China Health Industries Holdings Inc (CHHE)?
Our model-based price target is the fair value of $0.0001 (as of Sep 27, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the China Health Industries Holdings Inc stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus the last price from Sep 25, 2026 of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of China Health Industries Holdings Inc (CHHE)?
China Health Industries Holdings Inc reported trailing-twelve-month revenue of about $95.9K (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of China Health Industries Holdings Inc (CHHE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Health Industries Holdings Inc it is $0.0001 per share (as of Sep 27, 2026), against a price of $0.0001. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is China Health Industries Holdings Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, CHHE trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHHE?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For China Health Industries Holdings Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is China Health Industries Holdings Inc worth?
The market values China Health Industries Holdings Inc at about $6.6K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of China Health Industries Holdings Inc (CHHE)?
Balance-sheet figures for China Health Industries Holdings Inc (as of Sep 27, 2026): return on equity −6.9%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is CHHE from its 52-week high?
China Health Industries Holdings Inc trades at $0.0001, about 100% below its 52-week high of $0.2001 and at the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to China Health Industries Holdings Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is China Health Industries Holdings Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 58/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHHE calculated?
We run China Health Industries Holdings Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. China Health Industries Holdings Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of China Health Industries Holdings Inc (CHHE)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with China Health Industries Holdings Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of China Health Industries Holdings Inc
How large is the market capitalisation of China Health Industries Holdings Inc (CHHE)?
The market capitalisation of China Health Industries Holdings Inc is $6.6K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of China Health Industries Holdings Inc (CHHE)?
The price-to-sales ratio of China Health Industries Holdings Inc is 0.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of China Health Industries Holdings Inc (CHHE)?
Earnings per share at China Health Industries Holdings Inc are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of China Health Industries Holdings Inc (CHHE)?
The return on equity (ROE) of China Health Industries Holdings Inc is −6.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of China Health Industries Holdings Inc (CHHE)?
On an EBIT basis the return on assets of China Health Industries Holdings Inc is 3.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of China Health Industries Holdings Inc (CHHE)?
The operating margin of China Health Industries Holdings Inc is −163,513% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at China Health Industries Holdings Inc (CHHE)?
Earnings per share at China Health Industries Holdings Inc are growing −89.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does China Health Industries Holdings Inc (CHHE) generate?
The free cash flow of China Health Industries Holdings Inc is −$42.3M (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does China Health Industries Holdings Inc (CHHE) carry?
The net debt of China Health Industries Holdings Inc is $5.1M (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch China Health Industries Holdings Inc in the live analysis
One click puts China Health Industries Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026